Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof of Concept for Lenvatinib and Everolimus Prior to Cytoreductive Nephrectomy in Eligible Patients With Locally Advanced and Metastatic Renal Cell Carcinoma (RCC)

Trial Profile

Proof of Concept for Lenvatinib and Everolimus Prior to Cytoreductive Nephrectomy in Eligible Patients With Locally Advanced and Metastatic Renal Cell Carcinoma (RCC)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Everolimus (Primary) ; Lenvatinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 Planned number of patients changed from 13 to 15, Trial focus changed due to addition of Safety endpoint for primary outcome.
    • 16 Oct 2018 Planned End Date changed from 1 Nov 2019 to 30 Apr 2021.
    • 16 Oct 2018 Planned primary completion date changed from 1 Nov 2019 to 30 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top